Xeris reports Q4 product revenue $32.5M (+52% YoY); guides 2023 revenue $135-165M, cash flow breakeven Q4 2023

Xeris Biopharma Holdings, Inc.

Q4 net product revenue $32.5M, up 52% YoY; full-year 2022 net product revenue $109.3M, up 38% pro forma.
Q4 net loss $12.9M ($0.10/sh); full-year net loss $94.7M ($0.70/sh). Cash at Dec 31, 2022: $122.0M.
2023 guidance: total revenue $135M-$165M, cash utilization $57-77M, year-end cash $45-65M; targets cash flow breakeven in Q4 2023.
Announced research collaboration with Horizon Therapeutics for XeriJect formulation of TEPEZZA; $2.75M upfront payment.
Gvoke NRx market share >28% at Feb 2023; Recorlev granted FDA orphan-drug exclusivity.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xeris Biopharma Holdings, Inc. updated its the fourth quarter and full-year 2022 guidance (initiated).

Period: the fourth quarter and full-year 2022
Guidance: initiated
Result: reported results

Exact text from the filing

Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.